Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07440537 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Study sites: 26 to 27 · Start date changed from estimate of Mar 2026 to Apr 27, 2026v2 Show 2 more changesShow less
    • Study sites: 26 to 27
    • Start date changed from estimate of Mar 2026 to Apr 27, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).
Trial Details
NCT Number NCT07440537
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Cutaneous Lupus Erythematosus (CLE)
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov